The Human SARS-CoV-2 Spike (Trimer) Ig Total ELISA is a serology assay that measures and quantitates immunoglobulin (Ig) antibodies against SARS-CoV-2 Spike (Trimer) in human serum or plasma.
Principle of the method
The Human SARS-CoV-2 Spike (Trimer) Ig Total ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of Ig antibodies bound to SARS-CoV-2 Spike (Trimer). A trimerized Spike protein is pre-coated in the wells of the supplied microplate. Samples, controls, including a high control that can be used as a standard are then added into these wells and bind to the immobilized (capture) Spike protein. The wells are washed and Ig antibodies conjugated to HRP are added and will bind to any captured antibodies. The Ig Total antibody recognizes IgG, IgM and IgA. The wells are washed and a substrate solution is added that reacts with the enzyme complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of antibody present in the original specimen.
It has recently been shown that SARS (severe acute respiratory syndrome) is caused by a human coronavirus. Human coronaviruses are the major cause of upper respiratory tract illness, such as the common cold, in humans. Coronaviruses are positive-stranded RNA viruses, featuring the largest viral RNA genomes known to date (27-31 kb). The first step in coronavirus infection is binding of the viral spike protein, a 139-kDa protein, to certain receptors on host cells. The spike protein is the main surface antigen of the coronavirus. The glycosylated spike protein (as well as the nucleocapsid protein) can be detected in infected cell culture supernatants with antisera from SARS patients.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.